Hayriye Baykan, Hayrettin Kara, Ali Yaman, Tunay Karlıdere, Özgür Baykan, Onur Durmaz, Elif Gülşah Oğuz, Serap Akdeniz Gorgulu

Plasma Nesfatin-1 Levels and its Relationship with Anxiety Levels in Obesity Diagnosed Population: A Controlled Study

Objective: Nesfatin-1 is a satiety neuropeptide involved in the regulation of metabolic pathways and food intake. Some studies have shown nesfatin-1 to be also associated with stress responses and stress-related behaviors. In the present study, we evaluated nesfatin-1 levels in obese individuals and investigated whether nesfatin-1 levels could be associated with anxiety levels in obese populations. Methods: Fifty-eight obese (29 anxious and 29 non-anxious) patients and 25 healthy control subjects between 18 and 65 years old were enrolled in the study. Plasma nesfatin-1 levels were measured with a commercial enzyme-linked immunosorbent assay, and anxiety levels were measured using the Hospital Anxiety and Depression Scale.Results: Plasma nesfatin-1 levels were significantly lower in both obese and anxious subjects and obese and non-anxious subjects than in the control group. No significant differences were found between the obese+anxious group and the obese+nonanxious group.Conclusion: Our results suggest that plasma nesfatin-1 levels are decreased and not associated with anxiety levels in obese populations

Keywords:

Nesfatin-1, Obesity, Anxiety,

PDF

___

1. Stengel A, Mori M, Tache Y. The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors. Obes Rev 2013; 14: 859-870.
2. Stengel A, Tache Y. Role of brain NUCB2/nesfatin-1 in the regulation of food intake. Curr Pharm Des 2013; 19: 6955-6959.
3. Maejima Y, Kumamoto K, Takenoshita S, Shimomura K. Projections from a single NUCB2/nesfatin-1 neuron in the paraventricular nucleus to different brain regions involved in feeding. Brain Struct Funct 2016; 221:4723-4731.
4. Stengel A, Hofmann T, Goebel-Stengel M, Lembke V, Ahnis A, Elbelt U, Lamrecht NWG, Ordemann J,Klapp BF, Kobelt P. Ghrelin and NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects. Histochem Cell Biol 2013; 139: 909-918.
5. Ramanjaneya M, Addison M, Randeva HS. Possible role of NUCB2/ nesfatin-1 in adipogenesis. Curr Pharm Des 2013; 19: 6976-6980.
6. Ayada C, Toru U, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia 2015;19: 4-10.
7. Hofmann T, Ahnis A, Elbelt U, Rose M, Klapp BF, Stengel A. NUCB2/ nesfatin-1 Is Associated with elevated levels of anxiety in anorexia nervosa. PLoS ONE One 10(7): e0132058.
8. Tsuchiya T, Shimizu H, Yamada M, Osaki A, Oh IS, Ariyama Y, Takahashi H,Okada S,Hashimoto K,Satoh T,Kojima M,Mori M. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol (Oxf) 2010; 73: 484-490.
9. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxiety – and fear-related behaviors in the rat. Psychopharmacology (Berl) 2008; 201: 115-123.
10. Palasz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz R, Bajor G. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides 2012; 46: 105-112.
11. Shimizu H, Ohsaki A, Oh IS, Okada S, Mori M. A new anorexigenic protein, nesfatin-1. Peptides 2009; 30: 995-998.
12. Xu YY, Ge JF, Qin G, Peng YN, Zhang CF, Liu XR, Liang LC, Wang ZZ, Chen FH, Li J. Acute, but not chronic, stress increased the plasma concentration and hypothalamic mRNA expression of NUCB2/nesfatin-1 in rats. Neuropeptides 2015; 54: 47-53.
13. Bez Y, Ari M, Ozturk OH, Oktar S, Can Y, Sogut S. Plasma nesfatin-1 level may be associated with disease severity in patients with panic disorder. Bulletin of Clinical Psychopharmacology 2010; 20: 288-292.
14. Bez Y, Ari M, Ozturk OH, Oktar S, Can Y. Increased plasma nesfatin-1 levels in patients with obsessive compulsive disorder. Bulletin of Clinical Psychopharmacology 2012; 22: 5-9.
15. Gunay H, Tutuncu R, Aydin S, Dag E, Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012; 37: 194953.
16. Bahceci B, Bagcioglu E, Dilek AR, Celik FH, Bahceci I, Gonul Y, Hocaoğlu C. Is there any association between nesfatin-1 and generalized anxiety disorder? Bulletin of Clinical Psychopharmacology 2014; 24: 55-58.
17. Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 497500.
18. Emul M, Karamustafalioglu N, Kalelioglu T, Genc A, Tasdemir A,Gungor FC, Incir S, Seven A. The nesfatin 1 level in male patients with manic episode and alterations of nesfatin 1 level after antipsychotic and electroconvulsive treatment. J Affect Disord 2013; 151:84953.
19. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders-clinician version (SCID-CV), 1997. American Psychiatric Association Press, Washington DC 2007.
20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
21. Aydemir O, Guvenir T, Kuey L, Kultur S. Validity and reliability of Turkish version of hospital anxiety and depression scale. Turk Psikiyatri Derg 1997; 8: 280-287.
22. Basar O, Akbal E, Koklu S, Kocak E, Tuna Y, Ekiz F, Gültuna S,Yılmaz F.M,Aydoğan T. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012; 72: 479-483.
23. Guo Y, Xing M, Sun W, Yuan X, Dai H, Ding H. Plasma nesfatin-1 level in obese patients after acupuncture: a randomised controlled trial. Acupunct Med 2014; 32: 313-317.
24. Oh S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H,Yamamoto M,Imaki T,Hashimoto K,Tsuchiya T,Monden T,Horuguchi K,Yamada M,Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443:709-712.
25. Price CJ, Samson WK, Ferguson AV. Nesfatin-1 inhibits NPY neurons in the arcuate nucleus. Brain Res 2008; 1230: 99-106.
26. Hofmann T, Stengel A, Ahnis A, Buße P, Elbelt U, Klapp BF. NUCB2/ nesfatin-1 is associated with elevated scores of anxiety in female obese patients. Psychoneuroendocrinology 2013; 38: 2502-2510.
27. Hofmann T, Elbelt U, Ahnis A, Rose M, Klapp BF, Stengel A. Sexspecific regulation of NUCB2/nesfatin-1: Differential implication in anxiety in obese men and women. Psychoneuroendocrinology 2015; 60: 130-137.
28. Hofmann T, Weibert E, Ahnis A, Obbarius A, Elbelt U, Rose M, Klapp BF, Stengel A. Alterations of circulating NUCB2/nesfatin-1 during short term therapeutic improvement of anxiety in obese inpatients. Psychoneuroendocrinology 2017; 79: 107-115.
29. Goebel M, Stengel A, Wang L, Tache Y. Restraint stress activates nesfatin-1immunoreactive brain nuclei in rats. Brain Res 2009; 1300:114-124.
30. Massey SH, Backes KA, Schuette SA. Plasma oxytocin concentration and depressive symptoms: A review of current evidence and directions for future research. Depress Anxiety 2016; 33: 316-322.
31. Ozsoy S, Olguner Eker O, Abdulrezzak U. The Effects of antidepressants on neuropeptide Y in patients with depression and anxiety. Pharmacopsychiatry 2016; 49: 26-31.